(Alliance News) - Oncimmune Holdings PLC said Tuesday a study has found that the company's blood test product to speed lung cancer diagnosis deemed highly cost effective.
The cancer testing firm said that study was led by Leeds University Academic Unit of Health Economics, supported by NIHR Leeds in Vitro Diagnostics Co-operative and funded by The National Institute for Health Research's SBRI programme.
The study has shown that using Oncimmune's EarlyCDT Lung test was found to be more effective compared to computed tomography surveillance with an incremental cost-effectiveness ration of less than GBP2,500.
Oncimmune said its EarlyCDT Lung test is a simple enzyme-linked immunosorbent assay, ELISA, blood test that measures seven lung cancer-specific antibodies and can be used for the assessment of malignancy risk in patients with indeterminate pulmonary nodules.
The test can be run in any laboratory with standard laboratory equipment. A "kit" form of the test was CE marked in May 2017 for distribution to laboratories outside the USA, the company noted.
Adam Hill, chief executive officer, said: "Leeds University Academic Unit of Health Economics and NIHR Leeds MIC were excellent delivery partners for this project."
"Their support in bringing the multidisciplinary teams together from across the University and the local NHS Trust, enabled us to generate further data in support of our adoption discussions with the NHS across the UK," Hill said.
Oncimmune shares were trading 0.3% higher in London at 37.60 pence each on Tuesday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Oncimmune (ONC)